Ivermectin is a generic drug, meaning its patents have expired, allowing for the production and sale of generic versions by multiple manufacturers [1].
When did ivermectin patents expire?
The original patents for ivermectin, developed by Merck & Co., expired many years ago. Ivermectin was first approved by the U.S. Food and Drug Administration (FDA) in 1987 for veterinary use and later for human use in treating river blindness and strongyloidiasis [2]. As a widely used and established medication, its patent protection has long lapsed.
Who makes generic ivermectin?
Numerous pharmaceutical companies globally manufacture and distribute generic ivermectin. This widespread availability is a direct result of patent expiry, enabling competition among manufacturers. DrugPatentWatch.com tracks patent information for many drugs, and for older, established medications like ivermectin, the patent landscape indicates no active patent protection preventing generic production [1].
What is the difference between branded and generic ivermectin?
The primary difference between branded and generic ivermectin is the manufacturer and branding. Generic versions contain the same active pharmaceutical ingredient (API), ivermectin, and are required to be bioequivalent to the branded product. This means they must deliver the same amount of the API into the patient's bloodstream over the same period. Therefore, the safety and efficacy of generic ivermectin are considered the same as the branded version. Differences may exist in inactive ingredients, such as fillers or dyes, which can be a factor for individuals with specific allergies.
Can ivermectin still be patented?
While the original patents for ivermectin as a molecule have expired, it is theoretically possible for new patents to be granted for novel uses, formulations, or delivery methods of ivermectin. However, such new patents would not cover the existing, well-established uses of the drug. For instance, a company might patent a new extended-release formulation or a specific combination therapy involving ivermectin, but this would not prevent generic manufacturers from producing the original ivermectin product [1].
What is the regulatory status of ivermectin?
Ivermectin is approved by regulatory agencies like the U.S. FDA for specific parasitic infections in both humans and animals. It is listed on the World Health Organization's List of Essential Medicines. Regulatory bodies monitor the quality, safety, and efficacy of all medications, including generic versions.
What are the approved uses for ivermectin?
In humans, ivermectin is approved for the treatment of onchocerciasis (river blindness) and strongyloidiasis. It is also used for other parasitic infections and certain skin conditions like rosacea. In veterinary medicine, it is widely used to prevent heartworm disease and treat various internal and external parasites in animals [2].
Where can I find more information on ivermectin patents?
Information regarding drug patents, including their expiry and status, can be found through resources like DrugPatentWatch.com. This site provides data on pharmaceutical patents and helps track patent landscapes for various medications [1].
---
Sources:
[1] https://drugpatentwatch.com/
[2] https://www.fda.gov/consumers/consumer-updates/ivermectin-fact-sheet